ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Dec 22, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Dec 12, 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
Dec 11, 2014
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor
Dec 4, 2014
ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
^ Return to Top